STAG2 and melanoma: We focused on characterizing IRF9 as a direct target of STAG2 in melanoma cells (Fig. 3c), because that IRF9 is a central transcription factor in type I interferon signaling pathway17,18 and that motifs of several IRF family members were found to be enriched in the enhanced H3K27ac loop anchors (Fig. 2d).